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STUDIA MATHEMATICA
BULGARICA
MODELING DATA FOR COMPLICATIONS IN DIABETICS
USING LOGISTIC REGRESSION∗
K. Prodanova, S. Pashkunova
Abstract. A prospective study of the relationship between some clinical
parameters, genetic markers and complications of the patients with diabetes
is considered. About 200 patients (male and female) have been examined.
The patients are classified into five groups subject to the type of the diabetes.
Data obtained for each patient are related to the type of the complications –
macro vascular, retina pathology, neuron pathology and nephrite pathology,
12 clinical parameters and 7 genetic markers. Data for the same genetic
markers for 94 healthy persons (control group) are compared with those
of the diabetics patients. The association of the genetic markers and the
different types diabetes-related complications are investigated. A logistic
regression to identify which factors are associated with the complications is
performed. The associations between pathogenesis and gene genotypes are
investigated for the first time for the population of diabetics in Bulgaria.
1. Introduction. Diabetes mellitus (DM) is a chronic (long lasting), meta-
bolic disease which is characterized by high blood sugar (glucose). The human
metabolism consists of the most simple breakdown of food to basic molecules that
are used to provide energy and building material for body cells. The main energy
substrate of humans is glucose. In a healthy person the level of blood glucose is
regulated by several hormones, one of which is insulin. Insulin is produced by β-
cells of the pancreas. High levels of blood glucose result from lack of production of
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the hormone insulin or lack of “response” of the cells to insulin. DM (also called
diabetes only) is actually a lifelong disease that causes damage to blood vessels
and nervous system after a longer period of time. These injuries are manifested as
complaints from different organ systems such as the heart and circulatory system,
retina and eye, kidney, peripheral nerves, and others [1, 2, 3, 4, 5, 6, 7].
A survey of four diabetics related complications in patients of the Department
of Endocrinology of Military Medical Academy of Bulgaria, Sofia is presented.
Some clinical parameters and genetic markers are considered to be prognostic
factors of these complications. The patients are classified into five groups subject
to the type of the diabetes. A logistic regression is performed in order to identify
the clinical risk factors and risk gene genotypes which were associated with the
complications. The software package used for statistical modeling of real data
was STATISTICA 10 [8].
2. Measurements. During the study period 94 healthy subjects (control
group) and 206 patients (male and female) have been prospectively studied. The
patients were divided into 5 groups depending on the mode of inheritance, the
amount of insulin secretion, treatment and course of illness:
• Insulin-dependent type 1 diabetes (juvenile diabetes) – 43 patients;
• Insulin- not dependent type 2 diabetes mellitus (DM Age) – 60 patients;
• Insulin-dependent type 2 diabetes mellitus – 42 patients;
• Diabetes type MODY – 29 patients;
• Diabetes mellitus type LADA – 32 patients.
Data obtained for each patient included 12 clinical parameters as: Age (in
years), Sex, Glucosed Hemoglobin (HbAlc%), C-peptide, Creatinin, micro albu-
min, C-reactive Protein (CRP), Cholesterol, three-gliceridies (TRG), high den-
sity lipoprotein (HDL), low density lipoprotein (LDL), Duration (in years). The
complications which are observed are retinopathy, neuropathy, nephropathy and
macro vascular.
The primary data analysis was as follows: minimum age was 19 and maxi-
mum – 81 years, 35% of patients were men and 65% women, 23% was observed
retinopathy, minimum of duration is 1 year and maximum was 40 years, 75% had
neuropathy, in 21% nephropathy was observed and 18% was observed with macro
vascular complications. The sum of percentages is more than 100 because there
are patients with 2, 3 or 4 complications. In the study we also obtain data for
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genotypes of several genetic markers – Calpain, Leptin, MnSod, eNos, eNosGly,
LPL and AC in the patients and in the control group. The information about
mean values and standard deviations of the clinical parameters are presented in
Tables 2-7. More detailed information about the frequency distributions of gene
markers are published in [19].
An individual’s genotype is the combination of alleles found in that individual
at a given genetic locus [9]. Allele is a variant of the DNA level. In biological
systems, each parent transmits one allele with germ cells. So each person has two
alleles from their parents.
If there are two alleles in a population at locus A (denoted by A and a),
then the possible genotypes in that population are AA, Aa , and aa . Individuals
with genotypes AA and aa are homozygous (i.e., they have two copies of the
same allele). Individuals with genotype Aa are heterozygous (i.e., they have two
different alleles at the A locus). If the heterozygote is phenotypically identical
to one of the homozygous, the allele found in that homozygote is said to be
dominant, and the allele found in the other homozygote is recessive.
Allele demonstrates the power of gene mutation. If the allele is recessive,
it will be associated with a phenotype – for example have or not a neurological
complication only when is in a homozygous state – aa or AA. So in these phe-
notypic characteristics, which are given the absence or presence of symptoms -
nephrology, ophthalmology, etc., may be associated with dominant or recessive
mark.
In the nomenclature there are several signs for denoting the different allels:
“+” and “−” , T and L, T and G, G and A, etc.
The comparison of the genotypes distribution of considered gene markers in
our control group and in a healthy subjects from other countries shows that the
distribution is similar to other European populations [19].
3. Statistical Methods and Models.
3.1. Hardy-Weinberg equilibrium model. The mathematical concept,
called the Hardy-Weinberg equilibrium model or principle (HWP), is a crucial
concept in the population genetics [10, 11]. It predicts how gene frequencies will
be inherited from generation to generation given a specific set of assumptions.
The definition of HWP is the following [10, 11]: The stable frequency dis-
tribution of genotypes, AA, Aa , and aa , in the proportions p2, 2pq, and q2
respectively (where p and q are the frequencies of the alleles, A and a , p+ q = 1)
that is a consequence of random mating in the absence of mutation, migration,
natural selection, or random drift.
This principle is important because it gives biologists a standard for mea-
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suring changes in allele frequency in a population. When a population meets
all of the Hardy-Weinberg conditions, it is said to be in Hardy-Weinberg equi-
librium (HWE). Human populations do not meet all of the conditions of HWE
exactly, and their allele frequencies will change from one generation to the next
and the population will evolve. How far a population deviates from HWE can be
measured using the χ2 “goodness of fit” statistical test.
To test null hypothesis H0: {The frequencies of the genotypes in the control
group and in the group of patients with some type of diabetes are in Hardy-
Weinberg equilibrium} we use the statistic χ2 with 2 degrees of freedom at the
5%-level.
To test the null hypothesis H0: {The frequencies of allels of given marker in
the control group and in the group of patients with some type of diabetes are
equally likely} we use Fisher’s exact test for association [12, 13].
Table 1. Sample characteristics of clinical parameters for Type1 (N = 43)
Mean Minimum Maximum Std.Dev.
age 43.28 21.00 81.00 14.93
HbA1C 8.41 5.06 12.80 1.70
c-peptide 0.51 0.09 2.77 0.67
creatinin 4.98 0.80 41.10 7.96
micro albumin 85.58 51.00 128.00 17.37
CRP 68.51 0.00 626.00 135.48
Cholesterol 5.81 3.13 9.62 1.47
TRG 1.60 0.60 3.80 0.76
HDL 1.77 0.80 8.30 1.48
LDL 3.55 0.80 7.76 1.44
3.2. Dichotomous Response Models. Logistic regression model. The
regression model is used to relate a categorical response (dependent variable Y )
to the explanatory variables (predictors) x i(i = 1, . . . , c). We are interested in
the presence (coded by 1) or the absense (coded by 0) of the four categorical
responses
• Retinopathy,
• Neuropathy,
• Nephropathy,
• Macro vascular complications.
Modeling data for complications in diabetics 147
Table 2. Sample characteristics of clinical parameters for Type2 (N = 60)
Mean Minimum Maximum Std.Dev.
age 62.47 48.00 78.00 7.79
HbA1C 7.79 5.50 11.56 1.29
c-peptide 2.89 1.10 9.61 1.23
creatinin 89.85 59.00 128.00 15.55
micro albumin 22.64 0.00 300.00 52.67
CRP 4.46 0.77 14.00 2.80
Cholesterol 5.98 1.90 10.20 1.51
TRG 2.31 0.80 6.14 1.13
HDL 1.26 0.60 4.20 0.60
LDL 4.65 1.42 9.00 1.69
Table 3. Sample characteristics of clinical parameters for Type2 insulun (N = 33)
Mean Minimum Maximum Std.Dev.
age 57.70 44.00 73.00 7.78
HbA1C 9.67 6.10 13.80 1.72
c-peptide 87.73 56.00 192.00 25.15
creatinin 88.19 57.00 110.00 13.59
micro albumin 24.94 0.00 285.00 50.31
CRP 5.51 1.10 37.90 8.50
Cholesterol 5.75 2.59 9.40 1.47
TRG 1.85 0.60 8.06 1.45
HDL 1.13 0.26 1.70 0.34
LDL 4.01 1.78 8.70 1.52
At the first part predictors are 12 clinical parameters and the considered models
are 20 (4 complications in 5 groups of DM). At the second part the explanatory
variables are genotypes of the patients for 7 markers.
About the Dichotomous Response Models [15, 16, 17]: Let us define the
dummy random variable to indicate the two categories by Y = 1 for category A
and Y = 0 for B. The probability density for Y given the parameter p is therefore
point binomial
(1) f(Y/p) = pY (1− p)(1−Y ).
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Table 4. Sample characteristics of clinical parameters for LADA (N = 42)
Mean Minimum Maximum Std.Dev.
age 65.62 50.00 80.00 8.32
HbA1C 9.01 6.30 12.40 1.44
c-peptide 2.13 0.11 6.95 1.36
creatinin 96.10 59.00 256.00 34.22
micro albumin 95.74 0.00 831.00 186.73
CRP 7.77 0.50 47.70 8.07
Cholesterol 5.65 3.53 8.36 1.22
TRG 2.29 0.42 6.04 1.28
HDL 1.23 0.65 5.20 0.68
LDL 3.76 1.10 7.80 1.69
Table 5. Sample characteristics of clinical parameters for MODY (N = 31)
Mean Minimum Maximum Std.Dev.
age 41.00 19.00 68.00 10.44
HbA1C 8.29 4.70 11.40 1.93
c-peptide 3.41 0.98 6.50 1.27
creatinin 88.19 57.00 110.00 13.59
micro albumin 152.09 0.00 3600.00 658.04
CRP 5.27 0.20 23.00 4.92
Cholesterol 5.65 2.10 10.60 1.67
TRG 2.30 0.76 5.36 1.22
HDL 1.17 0.60 1.90 0.31
LDL 3.82 1.03 9.10 1.60
Table 6. Distribution of the gender in the different groups
Type of Diabetes female male
Type1 28 15
Type2 47 13
Type2-insulin 29 13
MODY 14 17
LADA 18 15
We assume that the probability p depends on a linear function
(2) d(x1, . . . , xc) = β0 +
c∑
i=1
βixi
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where xi(i = 1, . . . , c) are the explanatory variables (the independent variables),
βi are the constants. So, the joint conditional density is
(3) f(y1, . . . , yn/p(d1), . . . , p(dn)) = Π
n
j [p(dj)]
yi [1− p(dj)]
(1−yj ),
where n is size of a random sample of data y for response variable Y.
In order to be able to relate the value of y to the value of d a most specific
assumption about the form of p(d) is required. In the so called logit or logistic
model [5] the distribution function of logistic density is:
(4) p(d) =
ed
1 + ed
.
The shape of p(d) (logistic distribution) is quite similar to the shape for normal
distribution. The odds of a dichotomous response is given by
(5) o d d s =
[
p(d)
1− p(d)
]
.
The logit transformation
(6) ln
[
p(d)
1− p(d)
]
= d = β0 +
c∑
i=1
βixi
gives an important advantage of the model because Eq.(6) is a linear function of
the explanatory variables. The Newton-Raphson iterative procedure is usually
used to make maximal likelihood estimator βˆ of coefficient vector β in the logistic
model. The procedure is based on the preliminary estimator of β given by βˆ =
(XTX)−1XTY where Y is the vector of yi response values (i = 1, . . . , n) and
X(n × c) is the matrix of observations. The maximum likelihood is obtained by
solving the system of (c+ 1) equations:
(7)
n∑
i=1
pixi =
n∑
i=1
yixi
where
(8) pi = exp(x
T
i β)/(1 + exp(x
T
i β)).
The solutions to these equations given by βˆ can be used to obtain the estimator
pˆi for each of n observations and hence the fitted sum
∑n
i=1 pˆixi is equal to
the observed sum in the right side of (7). In comparison to the multiple linear
regression model, the coefficient vector βˆ must be interpreted differently:
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• The coefficients βˆ were interpreted as estimates of log odds .
• A marginal one unit increase in xj brings an increase in d ( i.e., in log odds)
of the amount βˆ.
Testing of hypothesis concerning the regression parameters can include a test
of single parameter, a test involving several parameters from the same regression,
and joint tests involving parameters from different regressions. In the polychoto-
mous logistic regression, tests for contribution of one or more parameters from
the same regression are usually constructed with a large sample Wald test, with
test statistic
(9) QW = βˆ
T [Var(βˆ)]−1βˆ,
where Var(βˆ) is the estimated covariance sub-matrix for the relevant parameters.
This statistics is approximately distributed as a χ2(r) random variable with r
degrees of freedom under the null hypothesis that r -dimensional vector βˆ is equal
~0. When there is a single parameter of interest the test statistic is
(10) QW = [βˆj/SE(βˆj)]
2
(SE(βˆj) is the standard error of βˆj) and its distribution is χ
2(r = 1).
4. Application to the real data. Results and conclusions. To test
the null hypothesis, that the frequencies of the genotypes in the control group
and in all other groups of diabetics are in Hardy-Weinberg equilibrium, we use
the package WinStat 4.3 [14]. In Table 8 the result of the test for the marker
eNOS in the control group is given. The conclusion is that the differences between
expected and observed frequencies is not statistically significant at the level of
significance α = 0.05, so the genotypes of marker eNOS in the control sample
meets the Hardy-Weinberg equilibrium.
Table 7. Hardy-Weinberg equilibrium of genotypes for marker
eNOS in the control group
Genotype eNOS Control group Expected Observed
Common homozygote (TT ) 60 61
Heterozygote (TL) 30.99 29
Rare homozygote (LL) 4 5
p-allele T frequency 0.79
P-level of χ2(2) 0.39
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The same tests for HWE about all other 7 markers are made for the control
group and for the other five groups of diabetics. For all samples we derive to be
in Hardy- Weinberg equilibrium [19].
Fisher’s exact test for association between the control group and each of the
other five groups of diabetics (for all 7 markers) have been carried out.
In Table 9 the result of Fisher’s exact test for Insulin-dependent type 1 dia-
betes is showed.
Table 8. Fisher’s exact test for marker eNOS in type 1 DM
Column 1 Column 2 Row-Totals
Alel T Alel L
Frequencies Control Group 151 39 190
Frequencies Type 1 65 21 86
Column totals 216 60 276
Fisher exact P, one-tailed p= 0.282
Fisher exact P, two-tailed p= 0.529
The two-tailed P value equals 0.529 and the conclusion is that the association
between rows (groups) and columns (outcomes) is not statistically significant at
5%-level for marker eNOS in Type 1 diabetes.
The result of Fisher’s exact test is that the association is statistically signifi-
cant for the gene marker MnSod in patients of dibetes type LADA:
Table 9. Fisher’s exact test for marker MnSod in LADA DM
Allele (+) Allele (−) Total P -value, two-tailed
LADA 34 (60.7%) 22 (39.3%) 56 P = 0.042
Control group 84 (44.7%) 104 (55.3%) 188
Our result for MnSod in LADA DM is similar to the one in [2]. The results of
all other Fisher’s exact tests have shown that the association is not statistically
significant at 5%-level as it is in [4, 6, 7]. Our results for eNOS are different from
[1] and [5], where the association is discovered to be significant.
Four logistic regressions for each of 5 groups DM have been considered, to
identify which of 12 clinical parameters (factors) were associated with the com-
plications (macro vascular, retinopathy, neuropathy and nephropathy). The re-
sulting models for retinopathy (for the different types of diabetics) are presented
in Table 11.
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Table 10. The statistical significant clinical factors associated with the complication
retinopathy identify by the logistic regression
Logistic regression models:
The complication Retinopathy as a function of clinical factors
Type Factor βˆ0 βˆi p-level odds ratio odds rat.
Diabetics (Wald’s (unit 95% conf.
χ2) change) interval
TYPE1 creatinin 1.487 −0.166 0.046 0.84 0.69–1.09
duration −0.133 0.009 0.88 0.81–0.97
TYPE 2 – c-peptide 1.117 −0.767 0.045 0.047 0.21–1.03
insulin
MODY cholesterol −8.135 0.822 0.022 2.28 0.91–5.72
LDL 1.134 0.033 3.11 0.83–11.63
LADA duration −4.062 0.341 0.014 1.41 1.06–1.86
From these results and according to the remarks in Subsection 3.3 we can
infer that the probability for retinopathy is higher when:
• The predictors “Creatinin” and “Duration” are lower in the patient with
type 1 DM;
• The predictor “C-peptide” is lower the patient with type 2-insulin DM;
• The predictor “Cholesterol” is higher in the patient with type MODY DM;
• The predictor “Duration” is higher in the patient with type LADA DM.
For the factor “Duration”, using (see [15]) minimum and maximum values in
the corresponding samples, we estimate that for type 1 DM (min = 1 and max =
40 years) with increase of years, the probability of complication “retinopathy”
decreased from 0.96 to 0.11, as for type LADA (min = 1 and max = 20 years)
this probability increases from 0.02 to 0.93.
The same type of analysis for macro vascular complications, neuropathy and
nephropathy have been carried out and published in Tables 11-13. Similar results
are published in [1], [2], [4], [18].
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Table 11. The statistical significant clinical factors associated with the complication
neuropathy identify by the logistic regression
Logistic regression models:
The complication neuropathy as a function of clinical factors
Type Factor βˆ0 βˆi p-level odds ratio odds rat.
Diabetics (Wald’s (unit 95% conf.
χ2) change) interval
TYPE1 duration 0.173 −0.071 0.049 0.93 0.85–1.01
TYPE2 gender −1.584 1.429 0.035 4.17 1.07–16.24
creatinin 0.041 0.048 1.04 0.99–1.09
TYPE 2 –
insulin cholesterol −4.781 2.301 0.039 9.99 1.04–19.00
TRG 0.761 0.048 2.13 0.98–4.66
MODY age −7.517 0.181 0.015 1.19 1.02–1.39
duration 0.428 0.005 1.53 1.12–2.01
LADA duration 0.533 −0.449 0.043 0.64 0.41–1.04
Table 12. The statistical significant clinical factors associated with the macro
vascular complications identify by the logistic regression
Logistic regression models:
Macro vascular complications as a function of clinical factors
Type Factor βˆ0 βˆi p-level odds ratio odds rat.
Diabetics (Wald’s (unit 95% conf.
χ2) change) interval
TYPE1 duration −4.552 0.118 0.033 1.12 1.01–1.27
age 0.091 0.026 1.09 1.01–1.19
creatinin 1.121 0.023 1.13 1.02–1.26
TYPE 2 –
insulin LDL −2.011 0.485 0.032 1.62 1.03–2.57
The main part of study is to investigate the association of the genetic markers
with the different types diabetes-related complications. For this purpose we make
two types of code clustering:
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Table 13. The statistical significant clinical factors associated with the complication
nephropathy identify by the logistic regression
Logistic regression models:
The complication nephropathy as a function of clinical factors
Type Factor βˆ0 βˆi p-level odds ratio odds rat.
Diabetics (Wald’s (unit 95% conf.
χ2) change) interval
TYPE1 c-peptide 1.443 −1342 0.034 0.26 0.07–0.94
TYPE 2 c-peptide −28.236 5.284 0.045 3.82 1.03–1.42
micro
albumin 0.123 0.016 1.05 1.01–1.09
MODY cholesterol −8.293 0.823 0.047 2.28 0.92–5.73
LDL 1.134 0.048 3.11 0.83–11.63
micro
LADA albumin −3.749 0.069 0.016 1.07 1.01–1.14
• genotypes AA and Aa (code1) versus aa (code2),
• genotypes aa and Aa (code1) versus AA (code2),
and than the respective 40 (4 complications in 5 groups and 2 types code clusters)
dichotomous response models with 7 predictors (markers) are built.
It turns out (see [4, 5]) that if we find differences in these two groups, we will
know if allele A or allele a is dominant.
The association between pathogenesis and gene genotypes of all types of di-
abetes are analysed using logistic regression. The results, when we assumed
a recessive model of inheritance (i.e., AA and Aa versus aa) for the group of
diabetes type 2, are given in Table 12. Lack of an increased risk of complication
posed by the A allele is not dominantly expressed and that the increased risk is
confined to aa homozygotes for:
• Calpain of neuropathy and macro vascular complications,
• LPL of nephropathy,
• MnSod of neuropathy,
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Table 14. Models of inheritance AA and Aa versus aa for the group of type
2 DM for diabetes-related complications
Diabetics type 2:
Genotypes AA and Aa (code1) versus aa (code2):
Complic- Gene βˆ0 βˆi p-level odds ratio odds rat.
ation marker (Wald’s (unit 95% conf.
χ2) change) interval
NEPHRO Calpain −5.128 2.014 0.041 7.5 1.1–53.7
LPL 2.1 0.04 8.1 1.01-66.9
NEURO MnSod −1.386 1.098 0.044 10.2 2.1–51.1
MACRO Calpain −4.678 1.992 0.019 7.3 1.3–40.6
eNos 2.322 0.035 10.2 1.1–93.1
RETINO eNosGly −4.388 1.471 0.011 4.3 1.2–27.1
AC 2.14 0.041 4.1 1.1–16.2
Table 15. Models of inheritance aa and Aa versus AA for the group of type
2 DM for diabetes-related complications
Diabetics type 2:
Genotypes aa and Aa (code1) versus AA (code2):
Complic- Gene βˆ0 βˆi p-level odds ratio odds rat.
ation marker (Wald’s (unit 95% conf.
χ2) change) interval
NEPHRO AC 0.209 −1.868 0.014 1.8 1.1–3.9
RETINO eNOS −4.738 1.742 0.047 1.6 1.0–7.7
• eNosGly of retinopathy
• AC of retinopaty and nephropathy.
By contrast, the increased risk of retinopathy (Table 8) is confined to eNOS
AA homozygotes for code cluster “aa and Aa versus AA”.
Our results imply that homozygosity for the eNos may be involved in predis-
position to retinopathy and macro vascular complications.
The results of association between pathogenesis and gene genotypes in other
groups of DM patients are published in [19] and are similar as in [1, 2, 3, 4, 5, 6, 7].
Using logistic regression the association between pathogenesis and gene geno-
types of all other types of DM are analysed and published in [19]. To our knowl-
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edge, this is the first study in Bulgaria to implicate polymorphisms of Calpain,
Leptin, MnSod, eNOS, eNosGly, LPL and AC as a genetic risk factor for retinopa-
thy, neuropathy, nephropathy and macro vascular complications.
In conclusion, we believe that our findings could contribute to any future
analyses validating these relationship.
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